Users Discontinuing Anti-Obesity Medications Gain Back Pounds Four Times Faster Than Those on Conventional Diets

Fresh analysis reveals that individuals who discontinue blockbuster weight-loss injections like semaglutide or tirzepatide can put back on lost weight far faster than those who halt traditional lifestyle plans.

Findings released in a leading health publication shows that while overweight individuals frequently drop about a fifth of their total mass while on the medication, the mass returns at an average rate of nearly a kilo each month upon discontinuation.

"Individuals buying these drugs need to be informed of the potential of quick rebound weight gain when the therapy ends," warns lead investigator Dr. Susan Jebb.

That rate of regain implies a return to original weight in about a year and a half.

Comparing Approaches

The study, which looked at dozens of trials involving over 9,000 of patients, contrasted the results of the injectable medications with conventional dieting.

The team note that people who shed pounds through lifestyle changes alone typically see a less rapid creep back—around 0.1 kg a month—once they finish.

Explaining the Fast Regain

Nutrition scientists suggest the mode of action of the injections is key to understanding the amplified regain.

The injections copy a body's own chemical called GLP-1, which moderates feelings of fullness.

"Long-term administration of GLP-1 concentrations several times higher than the body's typical production could lead to the system to produce less of its endogenous hormone, and could reduce responsiveness to its actions," explained Dr. Adam Collins, a nutrition researcher.

"Discontinuation of this hormone supplement results in hunger is no longer kept in check, making overeating much more probable."

A Lifelong Condition?

The NHS recommend the jabs for individuals with obesity-related medical conditions, accompanied by recommended diet and exercise modifications.

A number of clinicians contend that, given the high risk of weight regain, the therapy should be considered life-long.

This view is supported by pharmaceutical companies, who note that the findings "emphasize the long-term nature of obesity," comparing it to managing conditions like high blood pressure.

User Accounts

Users who have stopped the medication describe a intense resurgence of hunger.

"It was like a switch that goes on and you become starving," described an individual.

This challenge is worsened if users have not established sustainable lifestyle or habit changes during therapy.

Widespread Interest

Figures indicate that millions of adults in the UK have tried weight-loss jabs in the last 12 months, with interest being substantial.

• Use is more common among women than males.
• The 40s and 50s age group shows the highest level of interest.
• Many obtain the medications through private healthcare rather than public health services.

Ultimately, clinicians stress that while these medications are powerful tools for weight loss, they are not a permanent cure and maintained weight loss hinges on ongoing behavioural changes.